Plitidepsin (Aplidin®) received a negative recommendation across Europe
Plitidepsin (Aplidin®), a new medicine for the treatment of relapsed and/or refractory myeloma, has today received a negative recommendation from the Committee for Medicinal Products for Human Use (CHMP). The decision means that, as it stands, plitidepsin is unlikely to be made available for myeloma patients across Europe.